The Disparity in Access to New Medication by Type of Health Insurance
Lessons From Germany
Bibliographic Data
| ID | 9104463 |
|---|---|
| Authors | Karl J Krobot (University of North Carolina at Chapel Hill, corresponding author), William C Miller (0000-0003-3060-0210, University of North Carolina at Chapel Hill, corresponding author), Jay S Kaufman (0000-0003-1606-401X, University of North Carolina at Chapel Hill, corresponding author), Dale B Christensen (University of North Carolina at Chapel Hill), John S Preisser (0000-0002-7869-2057, University of North Carolina at Chapel Hill), Michel A Ibrahim, Michel Ibrahim (0000-0001-9624-0698, University of North Carolina at Chapel Hill, corresponding author) |
| Year | 2004 |
| Volume | 42 |
| Issue | 5 |
| Pages | 487-491 |
| Publication date | 2004-05-01 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Medical Care (JOURNAL) |
| Journal identifiers | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Publisher | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/01.mlr.0000124265.13559.02 |
| PMID | 15083110 |
| OpenAlex | W2058166221 |
| Language | EN |
| Citations received | 5 |
| References cited | 15 |
BACKGROUND: Drug provision within the German statutory health insurance system has undergone several reforms, including the introduction of drug macrobudgets in 1993. OBJECTIVE: The objective of this study was to investigate the extent to which statutorily (SHI) and fully privately (PHI) health-insured patients were provided with new medication recommended by professional bodies in an equitable fashion using the example of migraine patients. RESEARCH DESIGN: We conducted a retrospective cohort study. SETTING: A total of 367 primary-care practices (MediPlus, IMS Health) in Germany in the second year of the HealthCare Structural Reform Act were studied. SUBJECTS: Subjected consisted of 7703 SHI and 470 PHI migraineurs (International Classification of Diseases, 10th edition G43) aged 18 to 65 years at their first migraine prescription visit in 1994. OUTCOME MEASURE: We compared prescription of oral or subcutaneous serotonin 5HT1B/1D receptor agonist sumatriptan with nonserotoninergic migraine therapy. RESULTS: In multiplicative risk regression with variance estimation accounting for clustering of patients within practices, PHI patients were 2.3 times (95% confidence interval [CI], 1.6-3.3) more likely to receive sumatriptan than their SHI counterparts at the mean age of the cohorts (43 years) adjusted for incident versus prevalent migraine treatment, the gender of the patient, the age, gender, and primary care specialist group of the physician, and the type and the community size class of the practice. This disparity widened by 38% (95% CI, 1-88%) every 10 years of patient age. CONCLUSION: Even though virtually everyone in Germany has health insurance and drug coverage, use of new and recommended migraine medicines was less common among those with SHI compared with their privately insured counterparts. Systematic studies of access to health care recommended by professional bodies will be critically important to ensure delivery of high-quality health care for all patients
Agonist · Confidence interval · Family medicine · Health care · Medical prescription · Migraine · Psychiatry · Sumatriptan · Demography · Health and Medical Studies · Internal Medicine · Medication Adherence and Compliance · Medicine · Migraine and Headache Studies · Nursing · Pediatrics
The Comparison of Various Types of Health Insurance in the Healthcare Utilization, Costs and Catastrophic Health Expenditures among Middle-Aged and Older Chinese Adults
Utilization and out-of-pocket expenses of primary care among the multimorbid elderly in China
Holes in the Safety Net
The influence of insurance status on waiting times in German acute care hospitals
A conceptually based approach to understanding chronically ill patients’ responses to medication cost pressures
| Unique citing works | 5 |
|---|---|
| Citations per year | 0,25 |
| Citation span | 2006 - 2022 (17) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 5 |